PsO Pipeline Watch: Alumis Initiates Phase 3 Clinical Program Evaluating Its Oral TYK2 Inhibitor in Moderate-to-Severe Plaque PsO
Alumis Inc. is initiating the Onward Phase 3 Clinical Program evaluating ESK-001, an oral tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis. This Phase 3 program consists of two identical 24-week global Phase 3 clinical trials (ONWARD1 and ONWARD2) designed to evaluate the efficacy and safety of ESK-001 in adult patients with moderate-to-severe plaque psoriasis and […]